Tenaya Therapeutics Inc TNYA.OQ TNYA.O is expected to show no change in quarterly revenue when it reports results on March 2 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Tenaya Therapeutics Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $3.00, about 392.5% above its last closing price of $0.61
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.14 | -0.15 | -0.12 | Beat | 18.8 |
Jun. 30 2025 | -0.25 | -0.25 | -0.14 | Beat | 44 |
Mar. 31 2025 | -0.19 | -0.19 | -0.24 | Missed | -26.3 |
Dec. 31 2024 | -0.31 | -0.28 | Beat | 10 | |
Sep. 30 2024 | -0.35 | -0.37 | -0.30 | Beat | 18.4 |
Jun. 30 2024 | -0.39 | -0.39 | -0.34 | Beat | 13.1 |
Mar. 31 2024 | -0.42 | -0.42 | -0.40 | Beat | 5.4 |
Dec. 31 2023 | -0.50 | -0.44 | -0.40 | Beat | 8.8 |
This summary was machine generated February 27 at 21:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)